DCDaniele Campolungo

Daniele Campolungo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniele Campolungo has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The interferon-gamma response pathway is a targetable driver of FSHD muscular dystrophy progression

    by Beatrice Biferali, Federica Del Prete, Mara Salomè, Jose Manuel Garcia Manteiga, Reza Alemohammad, Miriam Mombellardo, Maria Pannese, Emanuele Mocciaro, Francesca Torri, İlKer Eren, et al.

    Facioscapulohumeral muscular dystrophy (FSHD) is a leading neuromuscular disorder caused by the aberrant expression of the transcription factor double homeobox 4 (DUX4) in skeletal muscle. While DUX4 is normally restricted to early embryonic development, its reactivation in FSHD triggers chronic inflammation and progressive muscle degeneration. However, the precise molecular links between DUX4 and persistent immune activation remain poorly understood. Here, we show that DUX4 induces a viral mimicry-like pathway that is fundamentally uncoupled from canonical type I interferon (IFN) activation. Instead, DUX4 establishes a non-canonical innate immune state dominated by IFN-γ signaling, providing a mechanistic explanation for the non-resolving inflammation characteristic of the disease. We demonstrate that while IFN-γ treatment alone is sufficient to recapitulate key DUX4 pathogenic effects, its inhibition rescues muscle inflammation and halts disease progression in FSHD models. These findings define a “skewed viral mimicry” process driven by a disease-specific transcription factor and identify IFN-γ as a primary therapeutic target for tissue-informed immunomodulation in muscular dystrophy.

  • Open Access

    DUX4-r exerts a neomorphic activity that depends on GTF2I in acute lymphoblastic leukemia

    by Daniele Campolungo, Mara Salomé, Beatrice Biferali, Anna Sofia Tascini, Davide Gabellini

    Translocations producing rearranged versions of the transcription factor double homeobox 4 (DUX4-r) are one of the most frequent causes of B cell acute lymphoblastic leukemia (B-ALL). DUX4-r retains the DNA binding domain of wild-type DUX4 but is truncated on the C-terminal transcription activation domain. The precise mechanism through which DUX4-r causes leukemia is unknown, and no targeted therapy is currently available. We found that the rearrangement leads to both a loss and a gain of function in DUX4-r. Loss of CBP/EP300 transcriptional coactivator interaction leads to an inability to bind and activate repressed chromatin. Concurrently, a gain of interaction with the general transcription factor 2 I (GTF2I) redirects DUX4-r toward leukemogenic targets. This neomorphic activity exposes an Achilles’ heel whereby DUX4-r–positive leukemia cells are exquisitely sensitive to GTF2I targeting, which inhibits DUX4-r leukemogenic activity. Our work elucidates the molecular mechanism through which DUX4-r causes leukemia and suggests a possible therapeutic avenue tailored to this B-ALL subtype.